Oncolytics Biotech Inc. (ONCY): Price and Financial Metrics

Oncolytics Biotech Inc. (ONCY): $1.02

0.13 (+14.21%)

POWR Rating

Component Grades

Momentum

D

Stability

D

Sentiment

Quality

C

Add ONCY to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#165 of 350

in industry

ONCY Price/Volume Stats

Current price $1.02 52-week high $3.39
Prev. close $0.89 52-week low $0.88
Day low $0.89 Volume 610,700
Day high $1.04 Avg. volume 427,615
50-day MA $1.27 Dividend yield N/A
200-day MA $1.85 Market Cap 75.91M

ONCY Stock Price Chart Interactive Chart >


Oncolytics Biotech Inc. (ONCY) Company Bio


Oncolytics Biotech Inc. discovers and develops pharmaceutical products for the treatment of cancers that have not been successfully treated with conventional therapeutics. The Company is focusing on the development of the reovirus known as REOLYSIN as a potential cancer therapeutic.


ONCY Latest News Stream


Event/Time News Detail
Loading, please wait...

ONCY Latest Social Stream


Loading social stream, please wait...

View Full ONCY Social Stream

Latest ONCY News From Around the Web

Below are the latest news stories about ONCOLYTICS BIOTECH INC that investors may wish to consider to help them evaluate ONCY as an investment opportunity.

Oncolytics Biotech® and SOLTI Present Positive Translational Data at SABCS

Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a clinical-stage immunotherapeutics company focused on oncology, today announced the presentation of additional translational data from the AWARE-1 breast cancer window-of-opportunity study conducted in combination with SOLTI-Innovative Cancer Research at The San Antonio Breast Cancer Symposium (SABCS).

Yahoo | December 7, 2023

Oncolytics Announces the Anal Cancer Cohort of the GOBLET Phase 1/2 Study of Pelareorep and Atezolizumab Has Met the Success Criteria for Efficacy

Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a clinical-stage immunotherapeutics company focused on oncology, today announced the presentation of positive, interim results from the Phase 1/2 GOBLET study evaluating the combination of pelareorep and atezolizumab...

Yahoo | November 9, 2023

Oncolytics Provides Update on Pancreatic Cancer Program for Pelareorep

Oncolytics Biotech® Inc. (NASDAQ: ONCY) (Oncolytics) (TSX: ONC), a clinical-stage immunotherapeutics company focused on oncology, provided an update on the planned program for pelareorep in pancreatic ductal adenocarcinoma (PDAC).

Yahoo | November 9, 2023

Oncolytics Biotech Inc. (NASDAQ:ONCY) Q3 2023 Earnings Call Transcript

Oncolytics Biotech Inc. (NASDAQ:ONCY) Q3 2023 Earnings Call Transcript November 3, 2023 Oncolytics Biotech Inc. misses on earnings expectations. Reported EPS is $-0.1 EPS, expectations were $-0.07. Operator: Good morning, and welcome to Oncolytics Biotech’s Third Quarter 2023 Conference Call. All participants are now in listen-only mode. There will be a question-and-answer session at the […]

Yahoo | November 5, 2023

Oncolytics Biotech® and SOLTI Present Further Positive Pelareorep Translational Data at SITC

Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a clinical-stage immunotherapeutics company focused on oncology, today announced the presentation of a poster that provides further positive translational data from the previously completed AWARE-1 breast cancer window-of-opportunity study, sponsored by SOLTI-Innovative Cancer Research, at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting.

Yahoo | November 3, 2023

Read More 'ONCY' Stories Here

ONCY Price Returns

1-mo -17.74%
3-mo -29.66%
6-mo -49.75%
1-year -38.55%
3-year -63.57%
5-year -53.21%
YTD -24.44%
2023 -17.18%
2022 17.27%
2021 -41.60%
2020 -50.00%
2019 162.98%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!